Livestream

Understanding the Pursuit of 3rd Line Therapies for Overactive Bladder: A Mixed Methods Study

Thursday, October 5, 2023

2:49 PM – 2:53 PM US PST

Location: Oregon Ballroom

Click to View Image
Image Label: Table 1

Click to View Image
Image Label: Table 2

Presenting Author(s)

Javier D. Gonzalez, MD (he/him/his)

Fellow - Urogynecology
Oregon Health & Science University
Portland, Oregon, United States

PDF

Co-Author(s)

LM

Leigh H. Martin, -

Medical Student
Oregon Health & Science University
Portland, Oregon, United States
ON

Olivia Nolan, MD (she/her/hers)

Obstetrics and Gynecology Resident
Oregon Health Science University
Portland, Oregon, United States
BG

Bharti Garg, MBBS, MPH

Statistician
Oregon Health & Science University
Portland, Oregon, United States
BO

Blake Osmundsen, MD (he/him/his)

Urogynecologist
Legacy Health
Portland, Oregon, United States
SC

Sara Cichowski, MD

Associate Professor and Fellowship Director
Oregon Health Science University
Portland, Oregon, United States

Disclosure(s):

Javier D. Gonzalez, MD: No financial relationships to disclose

Leigh H. Martin, -: No financial relationships to disclose

Olivia Nolan, MD: No financial relationships to disclose

Bharti Garg, MBBS, MPH: No financial relationships to disclose

Blake Osmundsen, MD: No financial relationships to disclose

Sara Cichowski, MD: No financial relationships to disclose

Patients suffering from OAB often spend well beyond the suggested timelines by AUA/SUFU between initiation of medical management (2nd line therapy) and effective third line therapies (intravesical OnabotulinumtoxinA, SNM, PTNS). We sought to identify obstacles and facilitators to pursuing third line therapy in the treatment of OAB using mixed research methods with a retrospective cohort study followed by key informant interviews. We found that our objective tools to identify patients likely to pursue third line therapies are lacking, We identified key facilitators and obstacles to pursuing effective third line therapies.